AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

HIV (Human immunodeficiency Virus) Therapeutics Market 2019-2023 | Evolving Opportunities with AbbVie Inc. and Gilead Sciences Inc. | Technavio

October 14, 2019 GMT
HIV (Human immunodeficiency Virus) Therapeutics Market 2019-2023 | Evolving Opportunities with AbbVie Inc. and Gilead Sciences Inc. | Technavio
HIV (Human immunodeficiency Virus) Therapeutics Market 2019-2023 | Evolving Opportunities with AbbVie Inc. and Gilead Sciences Inc. | Technavio

LONDON--(BUSINESS WIRE)--Oct 14, 2019--

Technavio has been monitoring the global HIV (human immunodeficiency virus) therapeutics market since 2016 and the market is poised to grow by USD 2.44 billion during 2019-2023, progressing at a CAGR of almost 2% during the forecast period. Request Free Sample Pages

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191014005484/en/

Technavio has announced its latest market research report titled global HIV therapeutics market 2019-2023. (Graphic: Business Wire)

Read the 175-page research report with TOC on “HIV (Human immunodeficiency Virus) Therapeutics Market Analysis Report by Type (combination therapy and monotherapy), by Product (reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors,integrase inhibitors, and coreceptor antagonists), by Geography (Asia, Europe, North America, and ROW), and Segment Forecasts, 2019 - 2023″.

The market is driven by the growing awareness about HIV and increasing number of initiatives to end the HIV epidemic. In addition, the advances in diagnostic testing for HIV is anticipated to further boost the growth of the HIV (human immunodeficiency virus) therapeutics market.

Various government organizations around the world are focusing on creating awareness about the development of novel medicines for the treatment of HIV. As a result, they are coming up with numerous initiatives such as Let’s Stop HIV, Stop HIV, Start Talking, and Stop HIV Stigma. They are also supporting the public health response to global HIV epidemic. Such initiatives and support are not only minimizing the annual incidence of HIV infection but also boosting the demand for HIV therapeutics among patients and healthcare units. Thus, the growing awareness about HIV and increasing number of initiatives to end the HIV epidemic are expected to drive market growth during the forecast period.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five HIV (Human immunodeficiency Virus) Therapeutics Market Companies:

AbbVie Inc.

AbbVie Inc. is headquartered in the US and owns and operates businesses under various segments such as pharmaceutical products. The company offers KALETRA, which is an anti-HIV-1 drug that contains two protease inhibitors, lopinavir and ritonavir. It offers these products for its end-users such as hospitals and pharmacies.

Boehringer Ingelheim International GmbH

Boehringer Ingelheim International GmbH is headquartered in Germany and manufactures products through business units including human pharmaceuticals, animal health, and biopharmaceuticals. The company offers Aptivus, which is a nonpeptidic protease inhibitor used to treat HIV infection.

Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co. is headquartered in the US and has business operations under various segments such as biopharmaceuticals. The company offers EVOTAZ, REYATAZ, and SUSTIVA for end-users such as hospitals and pharmacies. EVOTAZ is a combination of atazanavir/cobicista used to treat and prevent HIV infection.

F. Hoffmann-La Roche Ltd.

F. Hoffmann-La Roche Ltd. is headquartered in Switzerland and offers products through various business segments such as pharmaceuticals and diagnostics. The company offers INVIRASE, which is an antiretroviral drug used with other medications to treat and prevent HIV infection. It offers these products for its end-users such as hospitals and pharmacies.

Gilead Sciences Inc.

Gilead Sciences Inc. is headquartered in the US and offers a wide range of drugs through business units including pharmaceuticals. The company offers various medicines including BIKTARVY, STRIBILD, ATRIPLA, TRUVADA, DESCOVY, GENVOYA, COMPLERA, and ODEFSEY to its end-users such as hospitals and pharmacies.

Register for a free trial today and gain instant access to 10,000+ market research reports. Technavio’s SUBSCRIPTION platform

HIV (Human immunodeficiency Virus) Therapeutics Type Outlook (Revenue, USD Million, 2019 - 2023)

HIV (Human immunodeficiency Virus) Therapeutics Regional Outlook (Revenue, USD Million, 2019 - 2023)

Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more.Request a free sample report

Related Reports on Health Careare:

HIV-AIDS Testing Market – Global HIV-AIDS Testing Market by end-users (diagnostic laboratories, hospitals, and others) and geography (Asia, Europe, North America, and ROW).

Sexually Transmitted Disease (STD) Testing Market – Global Sexually Transmitted Disease (STD) Testing Market by product (laboratory testing devices and point of care (POC) testing devices) and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191014005484/en/

CONTACT: Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email:media@technavio.com

Website:https://www.technavio.com

KEYWORD:

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL AIDS HEALTH

SOURCE: Technavio Research

Copyright Business Wire 2019.

PUB: 10/14/2019 11:30 AM/DISC: 10/14/2019 11:30 AM

http://www.businesswire.com/news/home/20191014005484/en